A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors ; volume:97 ; number:2 ; year:2019 ; pages:102-111
Oncology ; 97, Heft 2 (2019), 102-111
- Urheber
-
Hong, David
Rasco, Drew
Veeder, Michael
Luke, Jason J.
Chandler, Jason
Balmanoukian, Ani
George, Thomas J.
Munster, Pamela
Berlin, Jordan D.
Gutierrez, Martin
Mita, Alain
Wakelee, Heather
Samakoglu, Selda
Guan, Shanhong
Dimery, Isaiah
Graef, Thorsten
Borazanci, Erkut
- DOI
-
10.1159/000500571
- URN
-
urn:nbn:de:101:1-2019081500400994578182
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hong, David
- Rasco, Drew
- Veeder, Michael
- Luke, Jason J.
- Chandler, Jason
- Balmanoukian, Ani
- George, Thomas J.
- Munster, Pamela
- Berlin, Jordan D.
- Gutierrez, Martin
- Mita, Alain
- Wakelee, Heather
- Samakoglu, Selda
- Guan, Shanhong
- Dimery, Isaiah
- Graef, Thorsten
- Borazanci, Erkut
Ähnliche Objekte (12)
Ibrutinib and novel BTK inhibitors in clinical development
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)
Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ibrutinib and novel BTK inhibitors in clinical development
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)
Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ibrutinib and novel BTK inhibitors in clinical development
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)
Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma